Ted Hibben, MBA
Chief Corporate Development Officer, Seraxis Inc.
• A Cambridge/Boston-based C-suite veteran of early- to mid-stage therapeutic platform biotechs: To date, forming over $3 billion in discovery and product R&D collaborations ($100M+ in upfronts); catalyzing nearly $1 billion in trade sales, mergers & IPOs; and raising ~$130M from over 20 VCs. • Scaled multiple therapeutic enterprises by providing commercial direction in governance by illuminating marketplace realities, partner interests and patient-oriented imperatives to guide corporate strategy and R&D focus, meanwhile building collaborative and productive corporate cultures. • R&D steering committee business representative for dozens of partnered and in-house programs ranging from target & drug discovery stage through Phase 3, across major therapeutic areas and rare disease, and in key modalities (small and large molecules, cell/biologics, vaccines). • Previous CBO at Totus Medicines (acting), Vaxess Technologies, Ceravance, Catabasis Pharmaceuticals, Ensemble Therapeutics (SVP), Cequent Pharmaceuticals, Coley Pharmaceutical Group.